Johnson & Johnson (NYSE:JNJ) Given New $287.00 Price Target at Royal Bank Of Canada

Johnson & Johnson (NYSE:JNJ) had its price objective raised by equities research analysts at Royal Bank Of Canada from $265.00 to $287.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target points to a potential upside of 11.74% from the company’s current price.

Other analysts also recently issued research reports about the stock. Weiss Ratings downgraded shares of Johnson & Johnson from a “buy (b)” rating to a “buy (b-)” rating in a research report on Monday, June 15th. The Goldman Sachs Group boosted their price objective on shares of Johnson & Johnson from $265.00 to $275.00 and gave the stock a “buy” rating in a research note on Wednesday, April 15th. Barclays upped their price target on shares of Johnson & Johnson from $234.00 to $255.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 15th. Johnson Rice set a $270.00 price objective on Johnson & Johnson in a research report on Friday, June 26th. Finally, HSBC set a $290.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research report on Monday, July 6th. Twenty investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $259.09.

Johnson & Johnson Trading Down 0.1%

Shares of JNJ traded down $0.14 during mid-day trading on Monday, reaching $256.84. The company had a trading volume of 755,169 shares, compared to its average volume of 8,372,100. Johnson & Johnson has a fifty-two week low of $154.80 and a fifty-two week high of $269.43. The firm has a fifty day simple moving average of $237.07 and a 200-day simple moving average of $233.23. The stock has a market cap of $618.27 billion, a price-to-earnings ratio of 29.65, a price-to-earnings-growth ratio of 2.51 and a beta of 0.24. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The business had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. During the same period last year, the company posted $2.77 EPS. The business’s quarterly revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 11.58 EPS for the current fiscal year.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.16% of the stock is owned by corporate insiders.

Institutional Trading of Johnson & Johnson

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in shares of Johnson & Johnson by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock valued at $49,740,362,000 after purchasing an additional 3,731,074 shares during the last quarter. State Street Corp boosted its position in Johnson & Johnson by 1.3% during the 4th quarter. State Street Corp now owns 133,869,843 shares of the company’s stock valued at $27,704,364,000 after purchasing an additional 1,663,782 shares during the period. Auto Owners Insurance Co boosted its position in Johnson & Johnson by 22,225.6% during the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock valued at $1,436,633,000 after purchasing an additional 69,108,368 shares during the period. Geode Capital Management LLC grew its stake in Johnson & Johnson by 3.1% during the 4th quarter. Geode Capital Management LLC now owns 57,953,747 shares of the company’s stock worth $11,967,947,000 after buying an additional 1,738,292 shares during the last quarter. Finally, Norges Bank acquired a new stake in Johnson & Johnson in the fourth quarter worth $6,924,523,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.